<1S-(1α,2α,3α,4α)>-2-<<3-<4-(6-cyclohexyl-1-oxohexyl)-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester | 144380-59-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: <1S-(1α,2α,3α,4α)>-2-<<3-<4-(6-cyclohexyl-1-oxohexyl)-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester
• 英文别名: [1S-(1α,2α, 3α, 4α)]-2-[[3-[4-(6-Cyclohexyl-1-oxohexyl)-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester；methyl 3-[2-[[(1S,2R,3S,4R)-3-[4-(6-cyclohexylhexanoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
• CAS: 144380-59-6
• 化学式: C₃₂H₄₃NO₅
• 分子量: 521.697
• InChiKey: YJMROBWYIPUPAW-MIFNPMPNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  38
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.66
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  <1S-(1α,2α,3α,4α)>-2-<<3-<4-(6-cyclohexyl-1-oxohexyl)-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester 在 盐酸 、 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 以52 mg (0.10 mmol, 81%)的产率得到<1S-(1α,2α,3α,4α)>-2-<<3-<4-(6-cyclohexyl-1-oxohexyl)-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid
  参考文献：
  名称：

  Heterocyclic ketone prostaglandin analogs

  摘要：

  前列腺素类似物在治疗血栓性和血管痉挛性疾病方面有用，其结构式为##STR1##其中：m为1、2或3；n为0、1、2或3；R.sup.1为氢、烷基、烯基、炔基、芳基烷基、芳基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基或杂芳基烷基，其中每个R.sup.1均未取代或可选地取代烷基、芳基、环烷基或环烷基烷基；R.sup.2为CO.sub.2 R CONHSO.sub.2 R.sup.3、CONHR.sup.4；R为氢、烷基或碱金属；X为O或NH；Y为--O--、单键或乙烯基，但当n为0时，Y不能为--O--；Z为--CH.dbd.CH--、--(CH.sub.2).sub.2--或##STR2##其余符号如规范中定义。

  公开号：

  US05135939A1
• 作为产物：
  描述：

  <1S-1α,2α,3α,4α>-2-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid, methyl ester 在 palladium hydroxide - carbon chromium(VI) oxide 、 四氯化碳 、 草酰氯 、 硫酸 、 氢气 、 1-羟基苯并三唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 N,N'-二环己基碳二亚胺 、 三苯基膦 、 copper(ll) bromide 作用下， 以 乙醚 、 二氯甲烷 、 氯仿 、 乙酸乙酯 、 丙酮 、 乙腈 、 苯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 68.92h， 生成 <1S-(1α,2α,3α,4α)>-2-<<3-<4-(6-cyclohexyl-1-oxohexyl)-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester
  参考文献：
  名称：

  Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists

  摘要：

  A series of interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles (2) were prepared and evaluated for their thromboxane (TxA2) antagonistic activity in vitro and duration of action in vivo. Examination of the carboxyl side chain indicated that the interphenylene ring substitution pattern and, to a lesser extent, chain length were important factors in determining TxA2 antagonistic potency. For the carboxyl side chain, ortho substitution, a single methylene spacer between the interphenylene and oxabicycloheptane rings, and a propionic acid side-chain length were determined to be optimal. With respect to the oxazole side chain a wide range of amide substituents with diverse structures and lipophilicities were compatible with potent antagonistic activity. Finally. an acidic functional group on the alpha-chain and a hydrogen bond acceptor on the 4-position of the oxazole ring were critical for potent activity. From the analogs prepared 42 {BMS-180,291: [(+)-1S-(1alpha,2alpha,3alpha,4alpha)]-2-[[3-[4-[(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid} was found to be a potent, selective, and orally-active TxA2 antagonist with a long duration of action and has been selected as a candidate for clinical development. In human platelet-rich plasma, 42 inhibited arachidonic acid (800 muM) and U-46,619 (10 muM) induced aggregation with I50 values of 7 and 21 nM, respectively. Radioligand binding studies of 42 with [H-3]-SQ 29,548 showed a K(d) value of 4.0 +/- 1.0 nM in human platelet membranes. Both in vitro and in vivo studies indicated 42 was devoid of direct agonistic activity. In vivo 42 (0.2 mg/kg, po) showed extended protection (T50 = 14.4 h) from U-46,619 (2 mg/kg, iv) induced death in mice, and a single oral dose of 42 (3 mg/kg) abolished U46,619-induced platelet aggregation ex vivo in African green monkeys for >24 h.

  DOI：

  10.1021/jm00062a013

文献信息

• Heterocyclic ketone prostaglandin analogs
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05135939A1

  公开（公告）日：1992-08-04

  Prostaglandin analogs useful in treating thrombotic and vasospastic disease having the structural formula ##STR1## wherein: m is 1, 2, or 3; n is 0, 1, 2 or 3; R.sup.1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl or heteroarylalkyl, each of R.sup.1 being unsubstituted or optionally substituted with alkyl, aryl, cycloalkyl, or cycloalkylalkyl; R.sup.2 is CO.sub.2 R CONHSO.sub.2 R.sup.3, CONHR.sup.4 ; R is hydrogen, alkyl, or alkali metal; X is O or NH; Y is --O--, a single bond or vinylene, except that Y cannot be --O--when n is O; Z is --CH.dbd.CH--, --(CH.sub.2).sub.2 --, or ##STR2## and the remaining symbols are as defined in the specification.

  前列腺素类似物在治疗血栓性和血管痉挛性疾病方面有用，其结构式为##STR1##其中：m为1、2或3；n为0、1、2或3；R.sup.1为氢、烷基、烯基、炔基、芳基烷基、芳基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基或杂芳基烷基，其中每个R.sup.1均未取代或可选地取代烷基、芳基、环烷基或环烷基烷基；R.sup.2为CO.sub.2 R CONHSO.sub.2 R.sup.3、CONHR.sup.4；R为氢、烷基或碱金属；X为O或NH；Y为--O--、单键或乙烯基，但当n为0时，Y不能为--O--；Z为--CH.dbd.CH--、--(CH.sub.2).sub.2--或##STR2##其余符号如规范中定义。
• Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists
  作者：Raj N. Misra、Baerbel R. Brown、Philip M. Sher、Manorama M. Patel、Steven E. Hall、Wen Ching Han、Joel C. Barrish、Octavian Kocy、Don N. Harris

  DOI：10.1021/jm00062a013

  日期：1993.5

  A series of interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles (2) were prepared and evaluated for their thromboxane (TxA2) antagonistic activity in vitro and duration of action in vivo. Examination of the carboxyl side chain indicated that the interphenylene ring substitution pattern and, to a lesser extent, chain length were important factors in determining TxA2 antagonistic potency. For the carboxyl side chain, ortho substitution, a single methylene spacer between the interphenylene and oxabicycloheptane rings, and a propionic acid side-chain length were determined to be optimal. With respect to the oxazole side chain a wide range of amide substituents with diverse structures and lipophilicities were compatible with potent antagonistic activity. Finally. an acidic functional group on the alpha-chain and a hydrogen bond acceptor on the 4-position of the oxazole ring were critical for potent activity. From the analogs prepared 42 BMS-180,291: [(+)-1S-(1alpha,2alpha,3alpha,4alpha)]-2-[[3-[4-[(n-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid} was found to be a potent, selective, and orally-active TxA2 antagonist with a long duration of action and has been selected as a candidate for clinical development. In human platelet-rich plasma, 42 inhibited arachidonic acid (800 muM) and U-46,619 (10 muM) induced aggregation with I50 values of 7 and 21 nM, respectively. Radioligand binding studies of 42 with [H-3]-SQ 29,548 showed a K(d) value of 4.0 +/- 1.0 nM in human platelet membranes. Both in vitro and in vivo studies indicated 42 was devoid of direct agonistic activity. In vivo 42 (0.2 mg/kg, po) showed extended protection (T50 = 14.4 h) from U-46,619 (2 mg/kg, iv) induced death in mice, and a single oral dose of 42 (3 mg/kg) abolished U46,619-induced platelet aggregation ex vivo in African green monkeys for >24 h.